

Trans-Lentiviral™ GIPZ Packaging System

Catalog numbers: TLP4614, TLP4615 (with cell line),
TLP4691 (Bulk-50rxns) and TLP4692 (Bulk-100rxns)

CONTENTS

Topic	Page
Product Description	1
Components of the Trans-Lentiviral GIPZ Packaging System	1
Biosafety Features	2
Protocols	4
Protocol I-Transfection and Virus Production	4
Protocol II-Concentrating Viral Particles	6
Protocol III-Transduction and Titering	7
Protocol IV-Puromycin Kill Curve and Puromycin Selection	11
Protocol V-Culturing TLA-HEK293T Cells	13
Packaging Plasmid Components	15
Related Reagents	19
FAQS	19
Troubleshooting	20
References	21
Licensing Information	22

PRODUCT DESCRIPTION

The Trans-Lentiviral GIPZ Packaging System allows creation of a replication-incompetent (Shimada *et al.* 1995), HIV-1-based lentivirus which can be used to deliver and express your shRNA of interest in either dividing or non-dividing mammalian cells. The Trans-Lentiviral GIPZ Packaging System uses a replication-incompetent lentivirus based on the trans-lentiviral system developed by Kappes *et al.* (2001).

Please note that GIPZ vectors are not compatible with third generation packaging systems such as ViraPower from Invitrogen. We recommend the Trans-Lentiviral Packaging System for use with our vectors.

COMPONENTS OF THE TRANS-LENTIVIRAL GIPZ PACKAGING SYSTEM

The Trans-Lentiviral GIPZ Packaging System possesses features which enhance its biosafety while allowing high-level shRNA expression in a wider range of cell types than traditional retroviral systems. The system includes the following major components:

- **Trans-Lentiviral packaging mix** - contains an optimized mixture of five packaging plasmids (pTLA1-Pak, pTLA1-Enz, pTLA1-Env, pTLA1-Rev and pTLA1-TOFF) to facilitate viral packaging of the transfer vector following co-transfection into TLA-HEK293T™ producer cells. These plasmids supply the helper functions as well as structural and enzymatic proteins *in trans* required to produce the lentivirus. For more information about the components for the packaging plasmids, see pages 14-17.
- **Optimized TLA-HEK293T producer cell line** - allows production of the lentivirus following co-transfection of the transfer plasmid and the packaging plasmids in the packaging mix. The cell line stably expresses the SV40 large T antigen and facilitates the production of high viral titers. *Optional – Not included in all configurations.*

- **Arrest-In transfection reagent** - a proprietary lipo-polymeric formulation, developed and optimized for transfection of shRNA plasmid DNA into the nucleus of cultured eukaryotic cells. Arrest-In also provides an enhanced uptake efficiency of the shRNA plasmid DNA into cells.
- **pGIPZ Non-Silencing control vector** - for use as an expression control. We recommend including the control vector in the co-transfection procedure to generate a control lentiviral stock that may be used to help optimize expression conditions in the mammalian cell line of interest. *Not included in bulk configurations.*
- **pGIPZ™ cloning vector** - the empty pGIPZ vector into which a TurboGFP reporter is cloned. The vector also contains the elements required to allow packaging of the expression construct into virions (e.g. 5' and 3' LTRs, Ψ packaging signal). *Not included in bulk configurations.*

BIOSAFETY FEATURES

The Trans-Lentiviral™ GIPZ Packaging System is based on lentiviral vectors developed by Kappes and Wu (Kappes *et al.* 2001; Kappes *et al.* 2003; Wu *et al.* 2000; Wu *et al.* 2001). This newest generation lentiviral system includes a significant number of safety features designed to enhance its biosafety and to minimize its relation to the wild-type, human HIV-1 virus. More significantly, the reverse transcriptase (RT) and integrase (IN) proteins are split from the native Gag-Pol polyprotein structure and are provided *in trans* from a separate plasmid producing a novel class of HIV-based vectors. Instead of expressing Gag-Pol, the Trans-Lentiviral system contains a plasmid that expresses Gag/Gag-Pro and one that expresses Pol (RT & IN) fused to Vpr. Removing the RT & IN from the packaging construct prevents the lentiviral replication machinery from functioning. This system, in contrast to the standard third generation vectors, prevents the generation of recombinant viral particles that possess the required functional Gag-Pol structure for DNA mobilization and the emergence of replication competent lentivirus.

Figure 1 illustrates the absence of functional Gag-Pol recombinants in lentiviral stocks generated from the Trans-Lentiviral GIPZ Packaging System.

Use of the Trans-Lentiviral GIPZ Packaging System to facilitate lentiviral-based expression of the gene of interest provides the following advantages:

- Generates an HIV-1-based lentivirus vector that effectively transduces both dividing and non-dividing mammalian cells.
- Efficiently delivers the gene of interest to mammalian cells in culture or *in vivo*.
- Eliminates the production of replication competent viral particles.




Figure 1. Stocks of lentiviral vectors were prepared using a third generation packaging construct (A), a third generation packaging construct in combination with a self-inactivating (SIN) (Shimada *et al.* 1995) vector (B), and the *trans*-vector (C), respectively. 10^8 infectious units of A and B and 10^9 infectious units of C were used to infect cultures of 293T cells containing the puromycin resistance gene. Three days later the culture supernatants were collected, concentrated by ultracentrifugation and used to infect HeLa-tat cells. After selecting in medium containing puromycin the resistant cell colonies were visualized by staining with crystal violet. Kappes & Wu, *Somatic Cell and Molecular Genetics*, Vol. 26, Nos. 1/6, November 2001.

The Trans-Lentiviral™ GIPZ Packaging System includes the following key safety features:

- The expression vectors contain a deletion in the 3' LTR ($\Delta U3$) that does not affect generation of the viral genome in the producer cell line, but results in “self-inactivation” of the lentivirus after transduction of the target cell (Shimada *et al.* 1995 and Zufferey *et al.* 1998).
- The number of genes from HIV-1 that are used in the system has been reduced (i.e. *gag*, *pol*, *rev*, *tat* and *vpr*).
- The VSV-G gene from Vesicular Stomatitis Virus is used to pseudotype the vector particles (Yee *et al.* 1994). The HIV-1 envelope has been completely removed from the vector.
- Genes encoding the structural and other components required for packaging the viral genome are separated onto four plasmids.
- Although the packaging plasmids allow expression *in trans* of genes required to produce viral progeny (e.g. *gag*, *pol*, *rev*, *tat*, *env*) in the TLA-HEK293T™ producer cell line, none of them contain LTRs or the Ψ packaging sequence. This means that none of the HIV-1 structural genes are actually present in the packaged viral genome, and thus, are never expressed in the transduced target cell. No new replication-competent virus has been shown to be produced.

Biosafety Level 2

We suggest the use of Biosafety Level 2 precautions when working with Trans-Lentiviral GIPZ Packaging System. For more information regarding viral agents and Biosafety Level 2 laboratory guidelines and precautions, please refer to the links below:

NIH Agent Summary Statement: <http://bmbi.od.nih.gov/viral2.htm#retro>
NIH Biosafety Level 2 Description: <http://bmbi.od.nih.gov/sect3bsl2.htm>
NIH/RAC “Guidance on Biosafety Considerations for Research with Lentiviral Vectors”:
http://www4.od.nih.gov/oba/RAC/Guidance/LentiVirus_Containment/pdf/Lenti_Containment_Guidance.pdf

PROTOCOLS

Producing Lentivirus in TLA-HEK293T™ Cells

Before a stably transduced cell line expressing the shRNA of interest can be created, a lentiviral stock (containing the packaged transfer vector) will first need to be produced by co-transfecting the optimized packaging plasmid mix and the transfer vector construct into the TLA-HEK293T cell line. Co-transfection of the Trans-Lentiviral packaging mix and the transfer vector containing the shRNA of interest into TLA-HEK293T cells will produce a replication-incompetent (Shimada *et al.* 1995) lentivirus, which can then be transduced into the mammalian cell line of interest. The following section provides protocols and instructions to generate a lentiviral stock.

Recommended Transfection Conditions

Produce lentiviral stocks in TLA-HEK293T cells using the following optimized amounts of transfection components below (see Table 1) and transfection conditions. The amount of lentivirus produced using these recommended component amounts and conditions generally results in a titer of approximately 1×10^6 transducing units (TU) per ml (unconcentrated). We recommend concentrating the viral stock to obtain a titer of approximately 1×10^8 transducing units (TU) per ml.

Table 1. Transfection Components.

Components	Amount
Tissue culture plate size	100mm (one per lentiviral construct)
Number of TLA-HEK293T™ cells to transfect	5.5×10^6 cells
Amount of Trans-Lentiviral™ Packaging Mix	28.5µg (26µl of packaging mix stock)
Amount of pGIPZ™ transfer vector	9µg
Amount of Arrest-In™ transfection reagent	187.5µg (187.5µl of 1mg/ml stock)

PROTOCOL I-TRANSFECTION AND VIRUS PRODUCTION

The protocol below is optimized for transfection of the shRNA plasmid DNA into TLA-HEK293T cells in a 100mm plate using serum free media. If a different culture dish is used, adjust the number of cells, volumes and reagent quantities in proportion to the change in surface area (Table 2).

In the days leading up to transfection, it is important to split or expand the cells 1:2 so that the cells are in a "rapid" replication state. This allows for the transcriptional and translational machinery of the cell to function at the highest level when generating virus.

It is preferable that transfections be carried out in medium that is serum free and antibiotic free. A reduction in transfection efficiency occurs in the presence of serum, however it is possible to carry out successful transfections with serum present. If the use of serum is required, transfection conditions will have to be re-optimized.

Warm Arrest-In to ambient temperature (approximately 20 minutes at room temperature) prior to use. Always mix well by vortex or inversion prior to use.

Maintain sterile working conditions with the DNA and Arrest-In mixtures as they will be added to the cells.

Table 2. Suggested amounts of DNA, medium and transfection reagent to deliver constructs into adherent cells.

Tissue Culture Dish	Surface area per well (cm ²)	Total serum free medium volume per well (ml)	Packaging mix plus Transfer vector plasmid DNA (µg)*	Transfection Reagent (µl)**
100 mm	56	5ml	37.5µg	187.5µl

*Recommended starting amount of DNA. May need to be optimized for the highest efficiency.

**Recommended starting amounts of transfection reagent. See Transfection Optimization.

1. The day before transfection (day 0), plate the TLA-HEK293T cells at a density of 5.5×10^6 cells per 100mm plate.

Full medium (i.e. with serum and antibiotics) will still be used at this stage.

2. On the day of transfection form the DNA/Arrest-In complexes.

The principle is to prepare the DNA and transfection reagent dilutions in an equal amount of serum-free medium in two separate tubes. These two mixtures (i.e. the DNA and the Arrest-In) will be added to each other and incubated for 20 minutes prior to addition to the cells. This enables the DNA/Arrest-In™ complexes to form.

- a. For each plate of cells to be transfected, dilute 37.5µg DNA into 1ml (total volume) of serum free medium in a microfuge tube.
- b. Dilute 187.5µl of Arrest-In into 1ml (total volume) of serum free medium in a separate microfuge tube.
- c. Add the diluted DNA (step a) to the diluted Arrest-In reagent (step b), mix rapidly then incubate for 20 minutes at room temperature.

This will give a 1:5 DNA:Arrest-In ratio which is recommended for successful transfection.

The total volume will be 2ml at this stage.

3. Aspirate the growth medium from the cells. Add an additional 3ml of serum free medium to each of the tubes containing the transfection complexes, mix gently, then overlay onto the cells. Return the cells to the CO₂ incubator at 37°C for 3-6 hrs.

The total volume will be 5ml at this stage.

4. Aspirate the transfection mixture and replace with 12ml standard culture medium. Return the cells to the CO₂ incubator at 37°C.
5. After 48-72 hours of incubation, examine the cells microscopically for the presence of TurboGFP expression which is an indication of transfection efficiency.

6. Harvest virus-containing supernatants 48-72 hours post-transfection by removing medium to a 15ml sterile, capped, conical tube.

If you are concentrating virus, you should harvest the supernatant at two intervals, 48 and 72 hours post-transfection. At 48 hours post-transfection, collect the supernatant into a 50ml sterile, capped, conical tube. Store the tube containing supernatant overnight at 4°C. To the 100mm plate, carefully pipette 12ml standard culture medium back onto the transfected cells and return plate to the CO₂ incubator at 37°C. The following day (72 hours post-transfection), harvest the culture supernatant and combine with supernatant harvested the day before. Follow the protocol below for concentration of the virus stock.

Caution: Remember that you are working with infectious virus at this stage. Follow the recommended guidelines for working with BL-2 organisms (see page 4 for more information).

7. Centrifuge tube containing harvested supernatant at 3000 rpm for 20 minutes at 4°C to pellet cell debris. Perform filtration step*, if desired.

**If you plan to use your lentiviral construct for in vivo applications, we recommend filtering your viral supernatant through a sterile, 0.45µm low protein binding filter after the low-speed centrifugation step to remove any remaining cellular debris. We recommend using Millex-HV 0.45µm PVDF filters (Millipore) for filtration.*

Transfection Optimization using Arrest-In™

It is essential to optimize transfection conditions to achieve the highest transfection efficiencies and lowest toxicity with your cells. The most important parameters for optimization are DNA to transfection reagent ratio, DNA concentrations and cell confluency. We recommend that you initially begin with the Arrest-In and DNA amounts indicated in Table 3 & 4 and the number of cells as listed in step 1 of the protocol for transfection and virus production. If a different culture dish is used, adjust the number of cells, volumes and reagent quantities in proportion to the change in surface area (see Table 4).

PROTOCOL II-CONCENTRATING VIRAL PARTICLES

We recommend that you concentrate your viral stock to obtain a higher titer. You will need to perform the filtration step first before concentrating your viral stock. You should expect your viral titer to increase at least 60-fold after concentrating. You should also expect a possible 30-50% loss in total viral yield.

1. Pipette supernatant into a sterile SW28 ultracentrifuge tube, centrifuge at 23,000 rpm for 1.5 hours at 4°C.
2. After ultracentrifugation, carefully aspirate and discard the supernatant.
3. Pipette the desired resuspension volume of DMEM (no serum) onto the pellet at the bottom of the tube. The minimum resuspension volume per pellet of supernatant collected from a 100mm plate is 100µl as it is difficult to resuspend in less volume. For one SW28 tube, which holds about 35ml of supernatant, we recommend resuspending in ~250µl.

4. The visible pellet is made up mostly of serum proteins from the culture media of the transfected cells. The viral particles need to be dislodged from this protein pellet. After adding the DMEM to the pellet, let it sit for 5-10 minutes then gently pipette up and down about 30 times trying to avoid formation of bubbles.
5. Transfer the resuspended pellet to a sterile microfuge tube and centrifuge at full speed for 3-4 minutes. This will pellet the serum proteins, which adhere to the bottom of the tube. After centrifugation, transfer the supernatant to a new microfuge tube and then aliquot into multiple vials.
6. Store aliquots at -80°C.
7. Proceed to Transduction and Titering.

Long-Term Storage

Place viral stocks at -80°C for long-term storage. Avoid freezing and thawing as it will result in loss of viral titer. When stored properly, viral stocks of an appropriate titer should be suitable for use for up to one year. After long-term storage, we recommend re-titering your viral stocks before transducing your mammalian cell line of interest.

PROTOCOL III-TRANSDUCTION AND TITERING

Follow the procedure below to determine the titer of your lentiviral stock using the mammalian cell line of choice. This protocol uses the TLA-HEK293T™ cell line that is available as part of the Trans-Lentiviral™ GIPZ Packaging System (Open Biosystems Catalog no. TLP4615).

Note: If you have generated a lentiviral stock of the expression control (e.g. pGIPZ™ Non-Silencing), we recommend titering this stock as well.

1. The day before transduction, seed a 24 well tissue culture plate with TLA-HEK293T cells at 5×10^4 cells per well in DMEM (10% FBS, 1% pen-strep).

*The following day, the well should be no more than 40-50% confluent.
TLA-HEK293T (Open Biosystems Catalog no. HCL4517).*

2. Make dilutions of the viral stock in a round bottom 96 well plate using serum-free media. Utilize the plate as shown in Figure 2 using one row for each virus stock to be tested. Use the procedure below (starting at step 4) for dilution of the viral stocks. The goal is to produce a series of 5 fold dilutions to reach a final dilution of 390625 fold.




Figure 2. Five-fold serial dilutions of virus stock.

3. To each well add 80µl of serum-free media.
4. Add 20µl of thawed virus stock to each corresponding well in column 1 (5 fold dilution).
Pipette contents of well up and down 10-15 times. Discard pipette tip.
5. With new pipette tips, transfer 20µl from each well of column 1 to the corresponding well in column 2.
Pipette 10-15 times and discard pipette tips.
6. With new pipette tips, transfer 20µl from each well of column 2 to the corresponding well in column 3.
Pipette 10-15 times and discard pipette tip.
7. Repeat transfers of 20µl from columns 3 through 8, pipetting up and down 10-15 times and changing pipette tips between each dilution.
It is strongly recommended that you use a high quality multichannel pipettor when performing multiple dilutions. Pre-incubate the dilutions of the virus stock for 5 minutes at room temperature.
8. Label 24 well plate as shown in Figure 3 using one row for each virus stock to be tested.




Figure 3. Twenty four well tissue culture plate, seeded with TLA-HEK293T™ cells, used to titer the virus.

9. Remove culture media from the cells in the 24 well plate.
10. Add 225µl of serum-free media to each well.
11. Transduce cells by adding 25µl of diluted virus from the original 96 well plate (in Figure 2) to a well on the 24 well destination plate (in Figure 3) containing the cells.

For example, transfer 25µl from well A2 of the 96 well plate into well A1 in the 24 well plate (see Table 3).

Table 3. Example of set up for dilutions

Well (Row A, B, C, or D)		Volume diluted virus used	Dilution Factor
Originating (96 well plate)	Destination (24 well plate)		
A1		25µl	5 *
A2	A1	25µl	25
A3	A2	25µl	125
A4	A3	25µl	625
A5	A4	25µl	3125
A6	A5	25µl	15625
A7	A6	25µl	78125
A8		25µl	390625 *

**Please note that when expecting very high or very low titers, it would be advisable to include either well 8 or well 1 respectively.*

12. Incubate transduced cultures at 37°C for 4 hours.
13. Remove transduction mix from cultures and add 1ml of DMEM (10% FBS, 1% Pen-Strep).
14. Culture cells for 48 hours.
15. Count the TurboGFP expressing cells or colonies of cells.

Count each multi-cell colony as 1 transduced cell, as the cells will be dividing over the 48 hour culture period. Figure 4 illustrates this principle of counting.

Note: Expression of the VSV-G glycoprotein causes HEK293T cells to fuse, resulting in the appearance of multinucleated syncytia. This morphological change is normal and does not affect production of the lentivirus.

16. Transducing units per ml (TU/ml) can be determined using the following formula:
of TurboGFP positive colonies counted x dilution factor x 40 = #TU/ml

Example: 55 TurboGFP positive colonies counted in well A3.

55 (TurboGFP positive colonies) x 625 (dilution factor) x 40 = 1.38×10^6 TU/ml




Figure 4. Examples of individual colonies.

Transduction and Analysis

Once you have generated a lentiviral stock with a suitable titer, you are ready to transduce the lentiviral vector into the mammalian cell line of choice and assay for knockdown of your gene of interest.

Multiplicity of Infection (MOI)

To obtain optimal expression of your shRNA, you will need to transduce the lentiviral vector into your mammalian cell line of choice using a suitable MOI. MOI is defined as the number of transducing units per cell. Although this is cell line dependent, this generally correlates with the number of integration events and as a result, level of expression.

Determining the Optimal MOI

A number of factors can influence determination of an optimal MOI including the nature of your mammalian cell, its transduction efficiency, your application of interest, and the nature of your gene of interest. If you are transducing your lentiviral construct into the mammalian cell line of choice for the first time, after you have titered it, we recommend using a range of MOIs (e.g. 0, 0.5, 1, 2, 5, 10, 20) to determine the MOI required to obtain optimal expression for your particular application. It should be noted that to achieve single copy knockdown, an MOI of 0.3 is generally used, as less than 4% of your cells will have more than one insert.

Expression Control

In general, we have found that 60-70% of the cells in an actively dividing cell line express a shRNA when transduced at an MOI of ~1. Some non-dividing cell lines transduce lentiviral constructs less efficiently. For example, only about 50% of the cells in a culture of primary

human fibroblasts express a shRNA when transduced at an MOI of ~1. If you are transducing your lentiviral construct into a non-dividing cell type, you may need to increase the MOI to achieve optimal expression levels of your shRNA.

PROTOCOL IV-PUROMYCIN KILL CURVE AND PUROMYCIN SELECTION

In order to generate stable cell lines, it is important to determine the minimum amount of puromycin required to kill non-transfected/transduced cells. This can be done by generating a puromycin kill curve.

Puromycin Kill Curve

1. On day 0 plate $5 - 8 \times 10^4$ cells per well in a 24 well plate in enough wells to carry out your puromycin dilutions. Incubate overnight.
2. Prepare media specifically for your cells containing a range of antibiotic, for example: 0 - 15 μ g/ml puromycin.
3. The next day (day 1) replace the growth media with the media containing the dilutions of the antibiotic into the appropriate wells.
4. Incubate at 37°C.
5. Approximately every 2 - 3 days replace with freshly prepared selective media.
6. Monitor the cells daily and observe the percentage of surviving cells. Optimum effectiveness should be reached in 1- 4 days under puromycin selection.
7. The minimum antibiotic concentration to use is the lowest concentration that kills 100% of the cells in 1 - 4 days from the start of antibiotic selection (see Figure 5).




Figure 5. Puromycin kill curve depicting cell death in relation to increasing doses of puromycin over time.

Puromycin Selection of Transduced Cells

1. On day 0 plate $5 - 8 \times 10^4$ cells per well in a 24-well plate. Incubate overnight.
2. Prepare media specifically for your cells containing the concentration of puromycin you selected based on the above "kill curve".
3. The next day (day 1), remove the medium and add the virus to the MOI you wish to use.

Bring the total volume of liquid up so that it just covers the cells efficiently with serum free media. If you are using concentrated virus you are likely to use very little virus volume and a lot of serum free media; if you are using unconcentrated virus you will find you need much more virus volume.

4. Approximately 6-8 hours post-transduction, add an additional 1ml of full media (serum plus pen/strep if you are using it) to your cells and incubate overnight.
5. At 48 hours post transduction, replace the full growth media with full growth media containing the puromycin into the appropriate wells. Incubate.
6. Approximately every 2-3 days replace with freshly prepared selective media.
7. Monitor the cells daily and observe the percentage of surviving cells as well as the level and total percentage of TurboGFP expression. At some time point almost all of the cells surviving selection will be expressing TurboGFP. Optimum effectiveness should be reached in 3-10 days with puromycin.

Please note that the higher the MOI you have chosen the more copies of the shRNA and puromycin resistance gene you will have per cell. When selecting on puromycin, it is worth remembering that at higher MOIs, cells containing multiple copies of the resistance gene can withstand higher puromycin concentrations than those at lower MOIs. Adjust the concentration of puromycin to a level that will select for the population of transduced cells you wish to select for, without going below the minimum antibiotic concentration you have established in your "kill curve".

8. Proceed to extract RNA for knock down evaluation by quantitative RT-PCR.




Figure 6. Residual GAPDH activity, as determined by quantitative RT-PCR, after transduction with a shRNA against GAPDH and puromycin selection at various concentrations.

PROTOCOL V-CULTURING TLA-HEK293T™ CELLS

TLA-HEK293T cells are cultured in a complete growth medium at 37°C with 5% CO₂. TLA-HEK293T cells detach easily from the culture dish surface. Therefore, handle the cells gently when replacing the culture medium or during washing.

Starting Cells from Frozen Cell Stock

1. Remove the TLA-HEK293T packaging cell line from liquid nitrogen and carry out a 'quick thaw'. Float the cells in the 37°C water bath for 2-5 minutes until nearly (~80%) thawed. *TLA-HEK293T stocks are frozen in 80% DMEM media, 10% fetal calf serum, and 10% DMSO, unless otherwise noted. Once cells are thawed, it is important to dilute the cells 1:10 in growth media immediately to reduce the potentially toxic effects of the DMSO preservative on the cells.*
2. Remove the cells from the vial and add slowly into a 15ml conical tube containing 10ml pre-warmed media.
3. Centrifuge for 3 minutes ~1000xg to pellet cells and remove the supernatant.
4. Add 14ml of media and transfer cells to a T25 flask or a 100mm culture dish.
5. Place the cells in the 37°C incubator with 5% CO₂.

Cell Maintenance

1. Fresh medium should be added to the cells every 3 days or as required by the growth rate of the cells.
2. TLA-HEK293T cells should always be treated very gently as they detach easily from the plate.

3. Add an appropriate volume of pre-warmed complete medium to the cells. You may first need to rinse the cells with PBS or media prior to feeding the cells.
This is typically done if there is a high degree of dead cells or debris in the culture, as would be expected after a thaw.
4. Return the cells to the 37°C incubator with 5% CO₂.

Sub-culturing/Passaging of Cells

1. TLA-HEK293T cells are passaged when they are 90% confluent to a ratio of 1:15 to 1:20 for general maintenance.
Cells can be passaged using a smaller ratio but will then reach confluency quicker and will need to be passaged more frequently (for example 1:5).
2. Carefully aspirate the growth media from the cells. This is best done by tilting the flask or plate and removing the medium without touching the cell surface.
3. Gently wash cells with PBS.
4. Trypsinize the cells (see Table 4). Place plate in the 37°C incubator for ~2 minutes for cells to release from the plate.
5. Add complete cell growth media to resuspend cells and inactivate the trypsin.
6. Pipette cells up and down ~5 times with a 10ml strip pipette to get a single cell suspension, while avoiding frothing of media.
7. Plate cells into new sterile flasks or plates containing complete growth medium (see Table 5). Place the cells at 37°C with 5% CO₂.

Table 4. Trypsinization and resuspension volumes for routinely used vessels.

Cell Culture Vessel	PBS Wash (ml)	Trypsin (ml)	Resuspension Cell Growth Media (ml)	Recommended Volume Media in New Flask (ml)
T-25 or 100mm	2.5	1	5-10	5-10
T-150	10	2	10	30-40
T-175	10	2	10	35-50

Table 5. Flask and plate surface areas and recommended volumes.

Flask Type	Growth Area Per Well (cm ²)	Volume Growth Media Per Well
T-175	175	35-50
T-150	150	30-40
100 mm dish	55	10
T-25	25	10
6 well	9.5	3
12 well	4	2
24 well	2	1
48 well	1	0.5
96 well	0.32	0.1
8 well chamber	0.8	0.4

PACKAGING PLASMID COMPONENTS




Figure 7. Cartoon schematic of the pTLA1-Pak plasmid.

Table 6. Components of the pTLA1-Pak plasmid.

Human cytomegalovirus (Tre-CMV)	RNA polymerase II promoter that permits high-level expression of the lentiviral <i>gag</i> and <i>pro</i> genes in mammalian cells.
<i>gag</i>	Virion structural proteins for forming the virion core and ribonucleoprotein complex within the core.
<i>pro</i>	Aspartyl-protease that cleaves the Gag, Gag-Pro, Gag-Pro-Pol polyproteins to produce viral proteins in their mature forms.
<i>rev</i>	Viral protein that binds to the RRE and facilitates the transport of unspliced and incompletely spliced mRNAs to the cytoplasm.
<i>tat</i>	Transcriptional activator of lentiviral gene expression, enhancing LTR-directed transcription.
polyA	Allows transcription termination and polyadenylation of the mRNA.
Ori	Permits high-copy replication and maintenance in <i>E. coli</i> .




Figure 8. Cartoon schematic of the pTLA1-Enz plasmid.

Table 7. Components of the pTLA1-Enz plasmid.

Human cytomegalovirus (CMV)	RNA polymerase II promoter that permits high-level expression of the lentiviral <i>RT</i> and <i>IN</i> genes in mammalian cells.
Vpr	Viral protein that shuttles the RT and IN into the viral particle.
RT	Reverse Transcriptase; DNA polymerase that copies RNA into DNA.
IN	Integrase; Enzyme responsible for inserting the linear double-stranded DNA copy of the lentiviral genome into host cell DNA.
RRE	Binding site for the Rev protein that aids in the transport of unspliced and singly-spliced RNAs from the nucleus to cytoplasm.
polyA	Allows transcription termination and polyadenylation of the mRNA.
Ori	Permits high-copy replication and maintenance in <i>E. coli</i> .




Figure 9. Cartoon schematic of the pTLA1-Env plasmid.

Table 8. Components of the pTLA1-Env plasmid.

Human cytomegalovirus (CMV)	RNA polymerase II promoter that permits high-level expression of the lentiviral VSV-G gene in mammalian cells.
VSV-G	Envelope G glycoprotein from Vesicular Stomatitis Virus to allow production of a pseudotyped lentivirus.
polyA	Allows transcription termination and polyadenylation of the mRNA.
Ori	Permits high-copy replication and maintenance in <i>E. coli</i> .




Figure 10. Cartoon schematic of the pTLA1-Rev plasmid.

Table 9. Components of the pTLA1-Rev plasmid.

Human cytomegalovirus (CMV)	RNA polymerase II promoter that permits high-level expression of the lentiviral <i>tat</i> and <i>rev</i> genes in mammalian cells.
<i>tat</i>	Transcriptional activator of lentiviral gene expression, enhancing LTR-directed transcription.
<i>rev</i>	Viral protein that binds to the RRE and facilitates the transport of unspliced and incompletely spliced mRNAs to the cytoplasm.
polyA	Allows transcription termination and polyadenylation of the mRNA.
Ori	Permits high-copy replication and maintenance in <i>E. coli</i> .




Figure 11. Cartoon schematic of the pTLA1-TOFF plasmid.

Table 10. Components of the pTLA1-TOFF plasmid.

Human cytomegalovirus (CMV)	RNA polymerase II promoter.
tTA	Transactivator protein that binds to the TRE in the absence of doxycycline and allows transcription through the minimal CMV promoter.
Ori	Permits high-copy replication and maintenance in <i>E. coli</i> .




Figure 12. Cartoon schematic of the pGIPZ shRNAmir transfer vector.

Table 11. Components of the pGIPZ shRNAmir transfer vector.

CMV	RNA polymerase II promoter that permits high-level expression of the lentiviral gag and pro genes in mammalian cells.
Ψ (Psi)	Region of viral RNA responsible for directing packaging.
PPT	Purine-rich sequence cleaved during reverse transcription to produce the RNA primer for synthesis of viral DNA.
wpre	Post-transcriptional regulatory element derived from the woodchuck hepatitis virus to increase vector independent expression levels of the transgene.
3' & 5' LTR	Long terminal repeat region composed of U3-R-U5 (5' to 3').
SIN	Deletion of the transcriptional enhancers & promoter in the U3 region of the 3' LTR.
RRE	Binding site for the Rev protein that aids in the transport of unspliced RNAs from the nucleus to cytoplasm.
TurboGFP	Green fluorescent protein utilized to track shRNAmir expression.
Puro	Puromycin-N-acetyl transferase, mammalian drug selectable marker.
shRNAmir	microRNA-30 flanking a stem-loop-stem structure.
polyA	Allows transcription termination and polyadenylation of the mRNA.
Ori	Permits high-copy replication and maintenance in <i>E. coli</i> .
Amp	Allows selection of the plasmid in <i>E. coli</i> .

RELATED REAGENTS

Table 12. Related Reagents

Reagent	Vendor	Catalog number
pGIPZ lentiviral shRNAmir constructs	Open Biosystems	RHS4430, RMM4431
GAPDH verified positive control-glycerol*	Open Biosystems	RHS4371
EG5 verified positive control-glycerol*	Open Biosystems	RHS4480
Non-silencing verified negative control-glycerol*	Open Biosystems	RHS4346
GAPDH verified positive control-viral particles	Open Biosystems	RHS4372
EG5 verified positive control- viral particles	Open Biosystems	RHS4584
Non-silencing verified negative control- viral particles	Open Biosystems	RHS4348
Arrest-In™ transfection reagent 0.5ml-10mls*	Open Biosystems	ATR1740-1743
pGIPZ™ empty vector	Open Biosystems	RHS4349
TLA-HEK293T packaging cell line	Open Biosystems	HCL4517

*these items also available in the lentiviral RNAintro shRNAmir starter kit (catalog number RHS4287)

FAQS

For answers to questions that are not addressed here, please contact technical support by calling 1-888-412-2225 or by emailing info@openbiosystems.com with your question.

Can cells other than TLA-HEK293T™ cells be used for packaging?

Yes, any standard 293T cells can be used for packaging your lentivirus. It is recommended to use a cell line that stably expresses the SV40 large T antigen to facilitate the production of high viral titers. Using a cell line without the SV40 large T antigen will result in low titers.

What media recipes are recommended to culture the TLA-HEK293T™ cells?

Recommended media recipes are listed below along with companies and catalog numbers that certain items can be purchased from.

1L of Media for TLA-HEK293T Cells

885ml DMEM High Glucose, with sodium pyruvate (Cellgro 10-013-CM)
100ml FBS (Hyclone SV30014.03)
10ml Pen/Strep (stock 10,000 I.U. Penicillin and 10,000mg/ml streptomycin) (Cellgro 30-002-CI)
5ml L-Glutamine (stock 200mM L-Glutamine, final concentration 1mM) (Cellgro 25-005-C3)

100ml of Media for Freezing TLA-HEK293T Cells

695ml DMEM High Glucose, with sodium pyruvate (Cellgro 10-013-CM)
200ml FBS (Hyclone SV30014.03)
5ml L-Glutamine (stock 200mM L-Glutamine, final concentration 1mM) (Cellgro 25-005-C3)
100ml DMSO (Calbiochem 317275)

Other reagents

DPBS 1X w/o calcium and magnesium (Cellgro 21-031-CM)
Trypsin/EDTA (Cellgro 25-053-CI)

After transfection, my TLA-HEK293T cells no longer look normal. Why is this?

Expression of the VSV-G glycoprotein causes HEK293T cells to fuse, resulting in the appearance of multinucleated syncytia. This morphological change is normal and does not affect production of the lentivirus.

What does the number 40 refer to in the formula for the calculation of titer?

The titer units are given in transducing units (TU) per ml, so the number 40 is used to convert the 25µl used in the titration ("volume of diluted virus used", Table 3) to one milliliter.

How can I make a stable cell line?

In order to generate stable cell lines, it is important to determine the minimum amount of puromycin required to kill non-transfected/transduced cells. This can be done by generating a puromycin kill curve. The purpose of a kill curve is to find out the minimum amount of puromycin that will kill your cells, so that you can use the minimum amount of puromycin to test for resistant colonies (so as not to kill all of your cells). We suggest that you perform serial dilutions until you find the lowest amount of puromycin that will kill your cells, starting with 0.5µg/ml. We purchase puromycin from Cellgro™. The catalog number is 61-385-RA.

Which Millipore filters do you use for the viral supernatant?

We use various filters dependent on volume size.

<50 mL: catalog number SCGP 005 25, either 0.22µm PES membrane or 0.45µm PVFD membrane,

150 mL: catalog number SCGP-U01-RE, Millipore Stericup express filter unit

500 mL: catalog number SCGP-U05-RE, Millipore Stericup express filter unit

1000 mL: catalog number SCGP-U11-RE, Millipore Stericup express filter unit

TROUBLESHOOTING

For help with packaging of your lentiviral construct, please contact technical support by calling 1-888-412-2225 or by emailing info@openbiosystems.com with your question.

If transfection into your cell line is unsuccessful, you may need to consider the following list of factors influencing successful transfection:

1. Concentration and purity of plasmid DNA and nucleic acids—determine the concentration of your DNA using 260nm absorbance. Avoid cytotoxic effects by using pure preparations of nucleic acids.
2. Insufficient mixing of transfection reagent or transfection complexes.
3. Transfection in serum containing or serum free media—our studies indicate that Arrest-In™/DNA complexes should preferably be formed in the absence of serum. In the cell lines tested we found that the highest transfection efficiencies can be obtained if the cells are exposed to the transfection complexes in serum free conditions followed by the addition of medium containing twice the amount of normal serum to the complex medium 3-6 hours post transfection. However, the serum free transfection medium can be replaced with normal growth medium if high toxicity is observed.
4. Presence of antibiotics in transfection medium—the presence of antibiotics can adversely affect the transfection efficiency and lead to increased toxicity levels in some cell types.
5. High protein expression levels—some proteins when expressed at high levels can be cytotoxic; this effect can also be cell line specific.
6. Cell history, density, and passage number—it is very important to use healthy cells that are regularly passaged and in growth phase. The highest transfection efficiencies are achieved if cells are plated the day before, however, adequate time should be given to allow the cells to recover from the passaging (generally >12 hours). Plate cells at a

consistent density to minimize experimental variation. If transfection efficiencies are low or reduction occurs over time, thawing a new batch of cells or using cells with a lower passage number may improve the results.

If Arrest-In™ seems to be toxic to a particular cell line, try reducing the DNA:Arrest-In ratio.

REFERENCES

Cited References:

Shimada, T., Shinya E., Miyake K. Development of Vectors Utilized for Gene Therapy for AIDS. AIDS. 1995; 4.

Kappes J.C., Wu X. Safety considerations in vector development. Somat Cell Mol Genet. 2001; 26(1-6):147-58.

Kappes J.C., Wu X., Wakefield J.K. Production of trans-lentiviral vector with predictable safety. Methods Mol Med. 2003; 76:449-65.

Wu X., Wakefield J.K., Liu H., Xiao H., Kralovics R., Prchal J.T., Kappes J.C. Development of a novel trans-lentiviral vector that affords predictable safety. Mol Ther. 2000; 2(1):47-55. PMID: 10899827.

Wu X., Wakefield J.K., Liu H., Kappes J.C. Analysis of lenti- and trans-lentiviral vector genetic recombination. Dev Biol (Basel). 2001; 106:237-48; discussion 249, 253-63. PMID: 11761237.

Yee J.K., Friedmann T., Burns J.C. Generation of high titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol. 1994; 43(Pt A):99-112. PMID: 7823872.

Zufferey R., Dull T., Mandel R.J., et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene therapy. J Virol 1998; 72:9873-9880.

Suggested Reading:

Coffin, J.M., Hughes, S.H., Varmus, H.E. Retroviruses. Cold Spring Laboratory Press. 1997. (<http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View..ShowTOC&rid=rv.TOC&depth=10>)

Liu H., Wu X., Xiao H., et al. Incorporation of functional human immunodeficiency virus type 1 integrase into virions independent of the Gag-Pol precursor protein. J Virol 1997; 71:7701-7710.

Wu X., Liu H., Xiao H. et al. Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J Virol 1999; 73:2126-2135.

Wu X., Liu H., Xiao H. et al. Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx. J Virol 1995; 69:338-3398.

LIMITED USE LICENSES

Limited Label License: Benitec

This product is sold solely for use for research purposes in fields other than plants. This product is not transferable. If the purchaser is not willing to accept the conditions of this label license, supplier is willing to accept the return of the unopened product and provide the purchaser with a full refund. However, if the product is opened, then the purchaser agrees to be bound by the conditions of this limited use statement. This product is sold by supplier under license from Benitec Australia Ltd and CSIRO as co-owners of U.S. Patent No. 6,573,099 and foreign counterparts. For information regarding licenses to these patents for use of ddRNAi as a therapeutic agent or as a method to treat/prevent human disease, please contact Benitec at licensing@benitec.com. For the use of ddRNAi in other fields, please contact CSIRO at www.pi.csiro.au/RNAi.

Limited Use Label License: CMV Promoter

The use of the CMV promoter is covered under U.S. Patent Nos. 5,168,062 and 5,385,839 owned and licensed by the University of Iowa Research Foundation and is sold for research use only. Commercial users must obtain a license to these patents directly from the University of Iowa Research Foundation (UIRF), 214 Technology Innovation Center, Iowa City, Iowa 52242. For further information, please contact the Associate Director of UIRF, at (319) 335-4546.

Limited Use Label License: Evrogen Fluorescent Proteins

This product contains a proprietary nucleic acid(s) coding for a proprietary fluorescent protein being, including its derivatives or modifications, the subject of pending U.S. and foreign patent applications and/or patents owned by Evrogen JSC (hereinafter "Evrogen Fluorescent Proteins"). The purchase of this product conveys to the buyer the non-transferable right to use Evrogen Fluorescent Proteins for (i) not-for-profit internal Research conducted by the buyer (whether the buyer is an academic or for-profit entity), where "Research" means non-commercial uses or activities which (or the results of which) do not generate revenue, and (ii) evaluation of Evrogen Fluorescent Proteins for the purpose of testing its appropriateness for development of a therapeutic, clinical diagnostic, vaccine or prophylactic product, provided that Evrogen Fluorescent Proteins are not used in the development or manufacture of such product. Offer of Evrogen Fluorescent Proteins for resale; distribution, transfer, or otherwise providing access to Evrogen Fluorescent Proteins to any third party for any purpose, or any use of Evrogen Fluorescent Proteins other than for Research is strictly prohibited. The buyer cannot sell or otherwise transfer materials made by the employment of Evrogen Fluorescent Proteins to a third party or otherwise use Evrogen Fluorescent Proteins for Commercial Purposes. The buyer may transfer information made through the use of this product solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of Evrogen Fluorescent Proteins in manufacturing; (2) use of Evrogen Fluorescent Proteins to provide a service, information, or data; (3) use of Evrogen Fluorescent Proteins for therapeutic, diagnostic or prophylactic purposes. The purchase of this product does not convey a license under any method claims in the foregoing patents or patent applications.

For information on the foregoing patents or patent applications or on purchasing a license to use Evrogen Fluorescent Proteins for purposes other than those permitted above, contact Licensing Department, Evrogen JSC, Miklukho-Maklaya street 16/10, Moscow, 117997, Russian Federation license@evrogen.com.

Limited Use Label License: Lentiviral Technology

The Trans-Lentiviral Technology is exclusively licensed from Tranzyme, Inc., under U.S. Patent Nos. 6,555,342, 6,362,000 and corresponding patents and applications in other countries for internal research purposes only. Use of this technology for gene therapy applications or bioprocessing other than for non-human research use requires a license from Open Biosystems. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer, including target validation applications in laboratory animals (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Open Biosystems, Inc. will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Open Biosystems, Inc. is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Open Biosystems, Inc. 6705 Odyssey Dr., Huntsville, AL 35806 (256) 319-1462.

Technical support: 1-888-412-2225

Fax: 1-256-704-4849

info@openbiosystems.com

Page 22

PB081808

For Research Use Only

shRNA Limited Use Agreement

Permitted Use. Portions of this product are covered by published patent applications (the "shRNA IP Rights") owned by Cold Spring Harbor Laboratory, referred to herein as "CSHL." This product, and/or any components or derivatives of this product, and/or any materials made using this product or its components, are referred to herein as the "Product." Subject to the terms of this Limited Use Agreement, sale of the Product by Open Biosystems ("OBS") conveys the limited, nonexclusive, nontransferable right to any company or other entity that orders, pays for and takes delivery of the Product (the "Customer") from OBS to use the Product solely for its internal research and only at such Customer's facility where the Product is delivered by OBS.

Restrictions. Customer obtains no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the Product, or to use the Product for the benefit of any third party or for any commercial purpose. The Product or components of the Product may not be used *in vitro* or *in vivo* for any diagnostic, preventative, therapeutic or vaccine application, or in the manufacture or testing of a product therefore, or used (directly or indirectly) in humans for any purpose.

Compliance. Customer may only use the Product in compliance with applicable local, state and federal laws, regulations and rules, including without limitation (for uses in the United States) EPA, FDA, USDA and NIH guidelines. Customer may not (directly or indirectly) use the Product, or allow the transfer, transmission, export or re-export of all or any part of the Product, in violation of any export control law or regulation of the United States or any other relevant jurisdiction.

Other Uses. Except for the permitted use expressly specified above and subject to the restrictions set forth above, no other use is permitted. CSHL shall retain all right, title and interest in and to the shRNA IP Rights. Nothing herein confers to Customer (by implication, estoppel or otherwise) any right or license under any patent of CSHL, including, for avoidance of doubt, under any patent that may issue from or relate to the shRNA IP Rights. For information on obtaining an agreement to use this Product for purposes other than those expressly permitted by this Limited Use Agreement, or to practice under CSHL patent rights, please contact the CSHL Office of Technology Transfer at (516) 367-8301.

Termination of Rights. Upon issuance of any patent covering any portion of the Product, any and all rights conveyed to any Customer (other than a research or educational institution that is a tax-exempt organization under section 501(c)(3) of the U.S. IRS code) under this Limited Use Agreement shall terminate and such Customer shall need a license from CSHL to continue to use any Product that was previously purchased, or to purchase from OBS or any other vendor or use any product claimed by such issued patent. At such time, such Customer may contact the CSHL Office of Technology Transfer at (516) 367-8301 and seek a license to use this Product under CSHL's patent rights.

YOUR USE OF THIS PRODUCT CONSTITUTES ACCEPTANCE OF THE TERMS OF THIS LIMITED USE AGREEMENT. If you are not willing to accept the limitations of this agreement, OBS is willing to accept return of the Product for a full refund.

Limited Warranty

Open Biosystems warrants that all of its products will perform according to specifications stated on the certificate of analysis. The company will replace, free of charge, any product that does not meet those specifications. This warranty limits Open Biosystems Corporation's liability only to the cost of the product. No warranty is granted for products beyond their listed expiration date. No warranty is applicable unless all product components are stored in accordance with instructions. Open Biosystems reserves the right to select the method(s) used to analyze a product unless Open Biosystems agrees to a specified method in writing prior to acceptance of the order.

Open Biosystems makes every effort to ensure the accuracy of its publications, but realizes that the occasional typographical or other error is inevitable. Therefore Open Biosystems makes no warranty of any kind regarding the contents of any publications or documentation. If you discover an error in any of our publications, please report it to our Technical Service Representatives.

Open Biosystems assumes no responsibility or liability for any special, incidental, indirect or consequential loss or damage whatsoever. The above limited warranty is sole and exclusive. No other warranty is made, whether expressed or implied, including any warranty of merchantability or fitness for a particular purpose.

©2007-2008 Open Biosystems, Inc. All rights reserved.

For research use only. Not intended for any animal or human therapeutic or diagnostic use.

Technical support: 1-888-412-2225
Fax: 1-256-704-4849
info@openbiosystems.com

Page 23

PB081808

For Research Use Only